Camellia japonica oil suppressed asthma occurrence via GATA-3 &amp; IL-4 pathway and its effective and major component is oleic acid

Zhang

et al. 2020

Preprint

Abstract Background: Allergic rhinitis (AR) is a global healthcare problem with obscure pathogenesis, and few studies have evaluated the association between AR and metabolomics. The aim of this study was to identify differences in serum metabolomics profiling of AR patients compared to healthy controls and to explore novel biomarkers reflecting disease severity.Methods: Serum samples were collected form 29 healthy controls and 72 AR patients, including 30 mild AR patients (MAR) and 42 moderate to severe AR patients (MSAR). Metabolomic profiling was performed by ultra-high performance liquid chromatography-mass spectrometry (UHPLC-MS) in serum samples. Orthogonal partial least square-discriminate analysis (OPLS-DA) was applied to assess the differences between AR patients and controls and for subgroups based on disease severity. Results: These analysis results successfully revealed distinct metabolite signatures which distinguished MAR patients and MSAR patients from health controls. In addition, MSAR patients also could be discriminated from MAR patients basing on their metabolic fingerprints. Most observed metabolite changes were related to pathways associated with glycine, serine and threonine metabolism, pyrimidine metabolism, sphingolipid metabolism, arginine and proline metabolism and fatty acid metabolism. Among these metabolites from dysregulated metabolic pathways, levels of sarcosine, sphingosine-1-phosphate (S1P), cytidine and linoleic acid significantly correlated with AR total nasal symptom score (TNSS) and visual analogue scale (VAS).Conclusions: MSAR patients have a distinctive serum metabolomics profile compared to MAR and health controls. These results suggest that metabolomic profiling may provide novel insights into pathophysiological mechanisms of AR and contribute to its evaluation of disease severity.

Section: Discussionmentioning

confidence: 99%

Serum Metabolomic Signatures Associated with Disease Severity in Allergic Rhinitis

Zhang

et al. 2020

Preprint

“…We followed the protocols of our previous study for animal testing ( Lee et al, 2019 ). Animal euthanasia guidelines were established prior to the start of the experiment and the experimenters checked the physical condition of all animals at least twice daily.…”

Section: Methodsmentioning

confidence: 99%

Saururus chinensis-controlled allergic pulmonary disease through NF-κB/COX-2 and PGE₂ pathways

Song

Lee

Kim

et al. 2020

PeerJ

Self Cite

Saururus chinensis is a perennial herb found in the northeastern regions of Asia, including Korea, China, and Japan, and is used in traditional medicine. Studies have identified the four major constituents in Saururus chinensis water extract (LHF618®) as miquelianin (11.75 ± 0.092 mg/g), rutin (1.20 ± 0.008 mg/g), quercitrin (2.38 ± 0.389 mg/g), and quercetin (0.068 ± 0.017 mg/g). Saururus chinensis can improve the symptoms of ovalbumin- or fine dust-induced allergic pulmonary disease by suppressing the effects of WBCs and neutrophils in BALF and IgE in the serum. Saururus chinensis dose-dependently recovered morphological changes such as mucous hyper secretion (from 2.7 ± 0.46 to 0.6 ± 0.65), pulmonary epithelial cell hyperplasia (from 2.4 ± 0.55 to 0.7 ± 0.67), and inflammatory cell infiltration (from 2.3 ± 0.45 to 0.6 ± 0.43), and effectively controlled cDNA levels and protein levels of IL-13. It inhibited NF-κB translocation and COX-2 protein synthesis and suppressed the expression of PGE2. Our results show that Saururus chinensis controlled allergic pulmonary disease via the anti-inflammatory pathways, NF-κB/COX-2 and PGE2. Saururus chinensis may be a promising drug candidate against fine dust-induced allergic pulmonary disease.

Evidence-Based Complementary and Alternative Medicine

“…Occurrence. We have previously reported the relationship between cytokines and chemokines and COPD severity [27]. In this study, the expressions of COPD-related cytokine genes IL-8 and TGF-β and chemokine genes CCL-2, CXCL1, CXCL9, CXCL10, and CXCL11 were measured.…”

Section: Macmoondong Decoction Significantly Downregulated the Dna Exmentioning

confidence: 98%

“…Histopathological analysis was conducted as previously described [27]. Lung tissues were fixed in 10% (v/v) formaldehyde solution, dehydrated in a graded ethanol series (99.9%, 90%, 80%, and 70%), and embedded in paraffin.…”

Section: Histopathological Analysismentioning

confidence: 99%

See 1 more Smart Citation

Herbal Medication, Macmoondong Decoction, Attenuates LPS‐Induced COPD in Small Airways via TGF‐β, CCL‐2, and CXCL1

Lee

Kang

Bae

et al. 2020

Self Cite

Chronic obstructive pulmonary disease (COPD) is an incurable disease related to the respiratory system. A 2017 report by the World Health Organization stated that it was the third most common cause of death in 2015. Macmoondong decoction is a prescription that has been used widely in Korea for the treatment of respiratory diseases, but there have been few investigations into the therapeutic mechanism. To investigate the anti-COPD effect of macmoondong decoction, the animals were divided into five treatment groups: control; COPD-induced control; Spiriva; 150 mg/kg macmoondong decoction; and 1500 mg/kg macmoondong decoction. Changes typically observed in COPD, such as the populations of WBC and neutrophils in BALF, the level of IgE in serum, morphological changes, the DNA levels, and the protein expression of cytokines and chemokines (TGF-β, CCL-2, CXCL1, and CXCL11) in the pulmonary system, were evaluated. Macmoondong decoction inhibited the populations of WBC and neutrophils in BALF and the level of IgE in serum. Dose-dependent prevention of the pulmonary morphological changes, such as emphysema and airway fibrosis, was observed. Macmoondong decoction suppressed the expression of DNA and proteins related to the occurrence of COPD, such as TGF-β, CCL-2, CXCL1, and CXCL11. In particular, the expression of TGF-β, CCL-2, and CXCL1 was significantly suppressed by 1500 mg/kg macmoondong decoction treatment compared with Spiriva treatment. Macmoondong decoction exerted an anti-COPD effect, and the mechanism of its action may be the suppression of TGF-β, CCL-2, CXCL1, and CXCL11 expression, which occurred in a dose-dependent manner. The mechanism of action of macmoondong decoction may be the dose-dependent suppression of TGF-β, CCL-2, CXCL1, and CXCL11, with TGF-β, CCL-2, and CXCL1 as the potential key factors involved in COPD suppression.